Sen. Markwayne Mullin Sells Off Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Senator Markwayne Mullin (R-Oklahoma) recently sold shares of Thermo Fisher Scientific Inc. (NYSE:TMO). In a filing disclosed on May 12th, the Senator disclosed that they had sold between $50,001 and $100,000 in Thermo Fisher Scientific stock on April 8th.

Senator Markwayne Mullin also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Texas Instruments (NASDAQ:TXN) on 4/8/2025.
• Sold $15,001 – $50,000 in shares of CSX (NASDAQ:CSX) on 4/8/2025.
• Sold $50,001 – $100,000 in shares of Lam Research (NASDAQ:LRCX) on 4/8/2025.
• Sold $15,001 – $50,000 in shares of Chevron (NYSE:CVX) on 4/8/2025.
• Sold $15,001 – $50,000 in shares of Zoetis (NYSE:ZTS) on 4/8/2025.
• Sold $15,001 – $50,000 in shares of ConocoPhillips (NYSE:COP) on 4/8/2025.
• Sold $50,001 – $100,000 in shares of Applied Materials (NASDAQ:AMAT) on 4/8/2025.
• Sold $15,001 – $50,000 in shares of Adobe (NASDAQ:ADBE) on 4/8/2025.
• Sold $50,001 – $100,000 in shares of Valero Energy (NYSE:VLO) on 4/8/2025.
• Purchased $15,001 – $50,000 in shares of Capital One Financial (NYSE:COF) on 3/19/2025.

Thermo Fisher Scientific Trading Up 7.2%

Shares of TMO opened at $432.16 on Tuesday. The firm’s fifty day moving average is $462.82 and its two-hundred day moving average is $513.70. The stock has a market cap of $163.14 billion, a PE ratio of 26.14, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 52-week low of $401.75 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. During the same quarter in the prior year, the company earned $5.11 EPS. Thermo Fisher Scientific’s revenue was up .2% compared to the same quarter last year. Research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were paid a $0.43 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.40%. The ex-dividend date was Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.09%.

Analysts Set New Price Targets

A number of equities analysts have weighed in on TMO shares. Stifel Nicolaus lowered their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a report on Wednesday, April 23rd. StockNews.com downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Friday, April 25th. Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Finally, Evercore ISI decreased their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Five research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $607.43.

Hedge Funds Weigh In On Thermo Fisher Scientific

Several institutional investors have recently bought and sold shares of the company. Cypress Advisory Group LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $253,000. S.E.E.D. Planning Group LLC raised its stake in shares of Thermo Fisher Scientific by 6.2% in the fourth quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company’s stock valued at $5,528,000 after acquiring an additional 618 shares in the last quarter. Czech National Bank grew its stake in Thermo Fisher Scientific by 6.6% during the 4th quarter. Czech National Bank now owns 82,934 shares of the medical research company’s stock worth $43,145,000 after purchasing an additional 5,118 shares in the last quarter. Granite Bay Wealth Management LLC purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth about $4,758,000. Finally, Courier Capital LLC boosted its stake in shares of Thermo Fisher Scientific by 148.8% in the 4th quarter. Courier Capital LLC now owns 20,914 shares of the medical research company’s stock valued at $10,880,000 after buying an additional 12,509 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president now directly owns 23,167 shares in the company, valued at $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now directly owns 115,174 shares of the company’s stock, valued at approximately $59,506,950.58. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 14,075 shares of company stock valued at $7,305,942. 0.33% of the stock is currently owned by corporate insiders.

About Senator Mullin

Markwayne Mullin (Republican Party) is a member of the U.S. Senate from Oklahoma. He assumed office on January 11, 2023. His current term ends on January 3, 2027. Mullin (Republican Party) ran in a special election to the U.S. Senate to represent Oklahoma. He won in the special general election on November 8, 2022. Mullin is a member of the Cherokee Nation and one of four Native American members of the 116th Congress. At the age of 20, Mullin took over his father’s plumbing business. He is also a former professional mixed martial artist. Markwayne Mullin graduated from Stilwell High School. Mullin earned an associate degree in construction technology from Oklahoma State University Institute of Technology. His career experience includes owning and founding multiple businesses.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.